New COVID-19 vaccine trialled in Hartlepool is approved for use

A new COVID-19 vaccine trialled by NHS staff in Hartlepool has been conditionally approved for use – to help fight rising cases and an increasing need to protect more people.

Reasearch vaccine trial team stand spaced out in hospital corridorThe national Novavax vaccine study, trialled at the University Hospital of Hartlepool, has been authorised by the European Regulator (EMA) and the World Health Organisation.

The team at Hartlepool includes staff from three of the region’s health trusts – North Tees and Hartlepool, South Tees Hospitals and Durham and Darlington – recruiting participants from across the region.

Kerry Colling, project manager of the Hartlepool site, said: “This is fantastic news for everyone involved in the trial.

“Staff from three trusts have come together, bringing collective knowledge which meant we were selected as one of the sites for the trial.

“The team have been ably supported by a group of volunteers who have welcomed and supported participant and performed routine checks including taking people’s temperature.

“And thank you to all of the participants for offering their time to be involved in this study and – in light of delays in the approval process – for their patience and support.

“Without outstanding team, support from our volunteers and the commitment of our willing participants, this new vaccine would not have been available for use.

“Together, we are helping protect people and to ultimately improve health outcomes and to save lives.”


Leave a comment

comments powered by Disqus